| Literature DB >> 31762578 |
Mohammad Moslem Imani1, Mohsen Safaei2, Aida Afnaniesfandabad3, Hedaiat Moradpoor4, Masoud Sadeghi5, Amin Golshah1, Roohollah Sharifi6, Hamid Reza Mozaffari7.
Abstract
INTRODUCTION: Enamel subsurface lesions or white spot lesions (WSLs) are commonly found in orthodontic patients with a prevalence of 5% to 97%. AIM: This systematic review aimed to evaluate the efficacy of casein phosphopeptide amorphous calcium phosphate (CPP-ACP) and casein phosphopeptide amorphous calcium phosphate fluoride (CPP-ACPF) for prevention and remineralization of WSLs in orthodontic patients in human randomized controlled clinical trials (RCTs).Entities:
Keywords: Casein phosphopeptide amorphous calcium phosphate; Casein phosphopeptide amorphous calcium phosphate fluoride; Orthodontics; White spot lesions
Year: 2019 PMID: 31762578 PMCID: PMC6853720 DOI: 10.5455/aim.2019.27.199-204
Source DB: PubMed Journal: Acta Inform Med ISSN: 0353-8109
PICOS process. Abbreviations: CPP-ACP: Casein phosphopeptide amorphous calcium phosphate; CPP-ACPF: Casein phosphopeptide amorphous calcium phosphate fluoride; WSL: White spot lesion
| Component | Description |
|---|---|
| Population | Participants included during and after fixed orthodontic treatment |
| Intervention | Products containing CPP-ACP or CPP-ACPF |
| Comparison |
Use of CPP-ACP vs. control (toothbrushing or fluoridated toothpaste), placebo, or other products (± fluoridated toothpaste) |
| Outcome | Changes in development of new WSLs and improvement of the appearance of the existing WSLs |
| Study design | Human randomized controlled clinical trials |
Figure 1.PRISMA flow diagram of study search
Figure 2:Cochrane risk of bias of the studies included in this systematic review: (A) graph and (B) summary
Characteristics of RCTs included in this systematic review (n=13) Abbreviations: CPP-ACP: Casein phosphopeptide amorphous calcium phosphate; CPP-ACFP: Casein phosphopeptide amorphous calcium phosphate fluoride
| First author, year | Country | Examination methods | Groups (n) | Study design | Follow-up period |
|---|---|---|---|---|---|
|
Bailey, 2009 ( | Australia | Clinical examination; quantitative light-induced fluorescence; digital photographs |
Placebo ( | Double-blind, parallel-group, randomized controlled trial | 3 months |
|
Beerens, 2010 ( | Netherlands | Clinical examination; quantitative light-induced fluorescence |
Control ( | Double-blind prospective, randomized controlled trial | 3 months |
|
Brochner, 2011 ( | Denmark | Clinical examination; quantitative light-induced fluorescence; digital photographs |
Control ( | Single-blind, randomized controlled trial | One month |
|
Robertson, 2011 ( | USA | Clinical examination; digital photographs |
Placebo ( | Double-blind, prospective, randomized controlled trial | 3 months |
|
Akin, 2012 ( | Turkey | Clinical examination; digital photographs |
Control ( | Parallel-group, prospective randomized controlled trial | 6 months |
|
Huang, 2013 ( | USA | Digital photographs |
Control (41), CPP-ACPF ( | Parallel-group, single-blind, active-controlled, randomized trial | 6 months |
|
Baroni, 2014 ( | Italy | Scanning electron microscopy (SEM) |
Control ( | Single-blind, prospective, randomized controlled trial | 6 months |
|
Groisman, 2015 ( | Brazil | Clinical examination; digital photographs |
CPP-ACPF ( | Randomized controlled trial | 12 months |
|
Singh, 2016 ( | India | Clinical examination; DIAGNOdent pen |
Control ( | Single-blind, randomized controlled trial | 6 months |
|
Karabekiroğlu, 2017 ( | Turkey | Clinical examination; DIAGNOdent pen |
Control ( | Single blinded-randomized controlled trial | 36 months |
|
Beerens, 2018 ( | Netherlands | Clinical examination; quantitative light-induced fluorescence |
Control ( | Double-blinded, prospective, placebo-controlled randomized clinical trial | 3 months |
|
Heravi, 2018 ( | Iran | Quantitative light-induced fluorescence |
Control ( | Single-blind, parallel-group, randomized, controlled trial | 3 months |
|
Rechmann, 2018 ( | USA | Clinical examination; quantitative light-induced fluorescence; digital photographs |
Fluoride rinse ( | Single-blind, prospective, randomized controlled trial | 12 months |
Summary of the findings of each study included in this systematic review (n=13). Abbreviations: CPP-ACP: Casein phosphopeptide amorphous calcium phosphate; CPP-ACPF: Casein phosphopeptide amorphous calcium phosphate fluoride, WSL: White spot lesion.
| First author, year | Summary of findings |
|---|---|
|
Bailey, 2009 ( | WSLs had a significantly greater chance of regression at 12 weeks following twice a day application of a remineralizing cream containing CPP-ACP compared with a placebo cream (P<0.05). |
|
Beerens, 2010 ( | There was no clinical advantage for use of CPP-ACPF compared to a fluoride-free control paste over a 12-week period. |
|
Brochner, 2011 ( | Topical treatment with CPP-ACP significantly decreased the change in fluorescence values (∆F) and area of the lesions after 4 weeks (P<0.05), but the improvement was not superior compared to daily use of fluoride toothpaste (control). |
|
Robertson, 2011 ( | CPP-ACPF prevented the development and decreased the number of WSLs, but the placebo had no preventive action. |
|
Akin, 2012 ( | CPP-ACP increased the remineralization of demineralized enamel more than fluoride rinse and control groups (P<0.05), but not the micro-abrasion group. |
|
Huang, 2013 ( | CPP-ACPF did not appear to be more effective than normal home or fluoride varnish care for improving the appearance of WSLs over an 8-week period. |
|
Baroni, 2014 ( |
CPP-ACPF had positive |
|
Groisman, 2015 ( | Commercially available CPP-ACPF paste was successful in enamel remineralization of WSLs during a 12-month follow-up of orthodontic patients, even when used for only for 4 weeks. |
|
Singh, 2016 ( | The use of fluoride varnish and CPP-ACPF cream had no superior efficacy compared to daily use of fluoride toothpaste alone (control) in reducing the severity of WSLs. |
|
Karabekiroğlu, 2017 ( | Daily use of CPP-ACP did not appear to be more effective than 1,450 ppm fluoridated toothpaste (control) for improving the appearance of WSLs after 36 months. |
|
Beerens, 2018 ( | Additional use of CPP-ACPF in patients with subsurface enamel lesions after fixed orthodontic treatment did not improve these lesions during one year after debonding. |
|
Heravi, 2018 ( | (I) Application of CPP-ACPF caused a significant decrease in the area of WSLs, which was significantly greater than that of the control group (P<0.05). (II) The mineral content of WSLs was enhanced in all groups throughout the experiment, but the degree of enhancement was significantly greater in CPP-ACPF than the control group. (III) A significantly greater improvement in the appearance of WSLs occurred following the use of CPP-ACPF as compared to patients receiving the usual home care (P<0.05). |
|
Rechmann, 2018 ( | (I) Daily application of CPP-ACPF resulted in no statistically significant difference in the sum of enamel decalcification index and international caries detection and assessment system scores. (II) Daily application of CPP-ACPF did not appear to significantly decrease the incidence of WSLs during fixed orthodontic treatment. |